Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525548 | 0.76 | SMN1; SMN2 (0.41) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL18467463 | 0.75 | CA12 (0.32) | NR1H2KMT2A | |
| SCHEMBL8630832 | 0.74 | SMN1; SMN2 (0.42) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL8630831 | 0.74 | SMN1; SMN2 (0.42) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL8634310 | 0.74 | SMN1; SMN2 (0.42) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL8634312 | 0.74 | SMN1; SMN2 (0.42) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL7411944 | 0.72 | ATM (0.46) | ATMSMN1; SMN2NR1H2HSD17B10 | |
| SCHEMBL5005297 | 0.72 | ATM (0.46) | ATMSMN1; SMN2NR1H2HSD17B10 | |
| SCHEMBL15481739 | 0.72 | ATM (0.54) | ATMSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL3850660 | 0.72 | ATM (0.46) | ATMSMN1; SMN2NR1H2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | ATM 1053/4885SMN1; SMN2 3035/4885NR1H2 1352/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ATM 1032/4885SMN1; SMN2 3526/4885NR1H2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.